Top Institutional Investors That Own Paratek Pharmaceuticals, Inc. (PRTK)

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is at least -5.27% than its current record low price of $11.85. There was a -15.28% decline on 04/19/2018 that led the price to move at $11.23. At recent session, the prices were hovering between $11.05 and $11.6. This company shares are 260.64% off its target price of $40.5 and the current market capitalization stands at $346.63M. The recent change has given its price a -17.28% deficit over SMA 50 and -61.29% deficit over its 52-week high. The stock witnessed -16.54% declines, -29.18% declines and -53.71% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PRTK’s volatility during a week at 5.18% and during a month it has been found around 4.46%.

Paratek Pharmaceuticals, Inc. (PRTK) Top Holders

Institutional investors currently hold around $311 million or 79.1% in PRTK stock. Look at its top three institutional owners. Omega Fund Management, Llc owns $34.46 million in Paratek Pharmaceuticals, Inc., which represents roughly 9.94% of the company’s market cap and approximately 11.08% of the institutional ownership. Similar statistics are true for the second largest owner, Baupost Group Llc/Ma, which owns 2,394,498 shares of the stock are valued at $31.73 million. The third largest holder is Blackrock Inc., which currently holds $25.22 million worth of this stock and that ownership represents nearly 7.28% of its market capitalization.

Paratek Pharmaceuticals, Inc. 13F Filings

At the end of 12/31/2017 reporting period, 62 institutional holders increased their position in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by some 2,363,775 shares, 59 decreased positions by 2,690,837 and 22 held positions by 18,405,271. That puts total institutional holdings at 23,459,883 shares, according to SEC filings. The stock grabbed 14 new institutional investments totaling 456,137 shares while 24 institutional investors sold out their entire positions totaling 1,651,413 shares.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Insider Trades

Multiple company employees have indulged in significant insider trading. Paratek Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chairman and CEO Bigham Michael has sold 8,700 shares of Paratek Pharmaceuticals, Inc. (PRTK) in trading session dated Apr. 09, 2018. These shares are worth $110,490 and were traded at $12.7 each. The SEC filing shows that Loh Evan performed a sale of 8,084 shares. The President, COO and CMO disposed these shares by way of transaction on Apr. 09, 2018. The company’s shares were given away at $12.7 per share worth to an income of some $102,667 on account of Loh Evan.

VP & Chief Commercial Officer, Woodrow Adam, sold 5,700 common shares of Paratek Pharmaceuticals, Inc. (PRTK) in the open market. In a transaction dated Apr. 09, 2018, the shares were put up for sale at an average price of $12.7, raking in a sum of $72,390. After this sale, 89,167 common shares of PRTK are directly owned by the insider, with total stake valued at $1,001,345.

In the transaction dated Apr. 09, 2018, the great number of shares disposed came courtesy the CFO; Pagan Douglas W. disposed a total of 5,237 shares at an average price of $12.7, amounting to approximately $66,510. The insider now directly owns 77,083 shares worth $865,642.

Paratek Pharmaceuticals, Inc. (PRTK) Analyst Guide

Several analysts have released their opinion on Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), with 8 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.11 average brokerage recommendation.